tirzepatide cv outcomes trial Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Real-world efficacy of tirzepatide in
Description
The synergy between these compounds addresses the primary limitation of GLP-1 medications: losing muscle alongside fat
This identifies why your body is holding weight and guides individualised protocol design.
Not necessarily
But after month 5, the tirzepatide patients begin to pull away from the semaglutide patients
